4DX's Principal Activity is the medical imaging software and hardware provider.
|Bid / Ask||-|
|Volume (4w avg)|
|vs Sector (1yr)||-11.90%|
|vs ASX 200 (1yr)||-25.32%|
|ASX Rank||563 of 2,295|
|Sector Rank||41 of 177|
4DMedical Limited (4DX) is a medical technology company aiming to deliver the global gold standard in respiratory diagnostics for all lung disorders including coronavirus, asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis and cancer. The company is based in Melbourne, Australia and Los Angeles, USA.
No incorporation details available.
DPS and Yield calculations use the Pay Date.
|No dividends paid.|
See Upcoming Dividends for all ASX companies.
|Mr Bruce Rathie||Non-Executive Chairman,Non-Executive Director||Dec 2019||
Mr Bruce Rathie
Non-Executive Chairman,Non-Executive Director
Mr Rathie is Non-Executive Directors nearly 20 years standing having completed prior careers in law and finance. His legal career included being a partner of a private law firm and then Senior Corporate Counsel to Robert Holmes a Court's Bell Resources Limited in the 1980's. After completing his MBA in Switzerland, he went into investment banking in 1986 which took him to New York for 3 years returning to Sydney in 1990. He spent the 1990's as an investment banker in Sydney, the last 5 of which as Director Investment Banking and Head of the Industrial Franchise Group at Salomon Brothers and then Salomon Smith Barney where he lead the firm's joint lead manager roles in the privatisations or IPOs of Qantas, Commonwealth Bank and Telstra amongst other major transactions of the day. Bruce has been a Director since 2000 in roles with ASX listed and unlisted companies mainly in the financial services, biotechnology and technology sectors. He is currently a Non-Executive Director of ASX 200 PolyNovo Limited, Capricorn Society Limited, ASX listed Netlinkz Limited and Australian Meat Processors Corporation Limited. He is also Chair of Capricorn Mutual Limited and 4DMedical. Previously, he has been a Non-Executive Director of ASX listed companies Compumedics Limited, Anteo Diagnostics Limited (Chair), USCOM Limited, Mungana Goldmines Limited and Datadot Technology Limited (Chair). He also served as an inaugural CSIRO nominated Non-Executive Director of Polynovo Biomaterials Pty Ltd when the Polynovo technology was first spun out of the CSIRO in 2004, as with several other CSIRO technology commercialisations and served as Chair of a number of these vehicles.
|Ms Lilian (Lil) Bianchi||Non-Executive Director||Dec 2019||
Ms Lilian (Lil) Bianchi
Ms Bianchi has experience in technology products and business transformations. She has participated in business transformations for US listed technology companies and risk collaborations across financial risk modelling, climate science and primary industry productivity models. She is an experienced contributor to business transformations for US-listed technology companies with technology product knowledge in AI and SaaS offerings and has international experience in the US, Australia, India, Singapore, UK, France, Germany, New Zealand, Italy and Spain. Lil's experience lies in her CEO, board, and senior executive roles in financial services, global listed tech corporations, tech start-ups, tier 1 management consultancies, public sector organisations, and international research operations. Lil is Chair of the Risk Committee.
|Mr John Andrew Livingston||Non-Executive Director||Mar 2018||
Mr John Andrew Livingston
Mr Livingston was previously one of the founding partners of Lake Imaging, subsequently becoming part of Integral Diagnostics Ltd., where John was CEO and Managing Director. John was awarded the AGFA International Award for Development of Digital Imaging Solutions in 2005. He has lectured in Australia and abroad on the digital radiology environment. John has commercial experience, having worked with the team at Lake Imaging and later Integral Diagnostics through acquisitions and the establishment of Greenfield facilities across Australia. During his career at Integral Diagnostics, John lead the group through private equity investment with Advent Partners in 2014 and in 2015 John worked with Advent to list Integral Diagnostics on the ASX. John is a former director of VicWest Community Telco and United Way, a current director at Comrad Medical Systems and Ballarat Clarendon College (Chair).
|Ms Lusia Halina Guthrie||Non-Executive Director||Dec 2017||
Ms Lusia Halina Guthrie
Ms Guthrie has over 35 years in the pharmaceutical and bioscience industries. She started her career as a Medical Laboratory Scientist before joining the Manufacturing Division of pharmaceutical company FH Faulding & Co (now Mayne Pharma). Lusia then went on to co-found medical technology innovation company LBT Innovations Limited (ASX:LBT) where she was Chief Executive Officer and Managing Director until 2016. Lusia has worked in the Australian life sciences sector through various engagements including: Chair of BioMelbourne Network; Chair of the Medical Device Partnering Program in Victoria; and Chair Australian Lung Health Initiative. She is also a member of the Innovation Taskforce, an initiative of the Victorian Government Minister for Jobs, Innovation and Trade. Lusia also serves on several advisory boards: Medicines Manufacturing Innovation Centre at Monash University; Australian Institute for Machine Learning at the University of Adelaide; and Australian Regenerative Medicine Institute. Lusia is a member of the Risk Committee.
|Mr Julian Bernard Kingsley Sutton||Non-Executive Director||Sep 2017||
Mr Julian Bernard Kingsley Sutton
Mr Sutton started his career in 1995 as an actuarial analyst for Towers Perrin in Melbourne where he consulted to some of Australia's superannuation funds. He later transferred with Towers Perrin to Brussels and then to London, where he worked mainly in an asset consulting capacity. In 2002, Julian joined Credit Suisse Asset Management in London as an assistant portfolio manager in their Multi-Manager team. In 2004, Julian joined Schroders Investment Management as a Senior Portfolio Manager in the Multi-Asset team, responsible for the management of a suite of investment funds with assets under management. After seven years with Schroders, Julian returned to Australia with entrepreneurial ambitions. Currently, Julian is responsible for the sales and marketing function of Brown Advisory in Australia.
|Dr Robert Alan Figlin||Non-Executive Director||Dec 2016||
Dr Robert Alan Figlin
Dr Figlin is a Professor of Medicine and Biomedical Sciences and the Steven Spielberg Family Chair in Hematology-Oncology, Director of the Division of Hematology-Oncology, Deputy Director of the Samuel Oschin Comprehensive Cancer Institute and Deputy Director of Integrated Oncology at Cedars-Sinai Medical Center in Los Angeles, California. He completed his residency and chief residency in internal medicine at Cedars-Sinai Medical Center and a fellowship in hematology/oncology at the David Geffen School of Medicine at University of California, Los Angeles (UCLA). He is an Emeritus Professor of Medicine and Urology at the David Geffen School of Medicine at UCLA. Robert serves as Editor for Kidney Cancer Journal, and his studies have appeared in Clinical Cancer Research, Journal of Clinical Oncology, New England Journal of Medicine, Lancet, JNCI, Lancet Oncology, and Journal of Urology, among others. He has authored over 350 peer reviewed articles, more than 70 book chapters, and has published, as Editor, multiple books on kidney cancer. He is the Editor of the Springer Science book entitled, Renal Cell Carcinoma: Translational Biology, Personalized Medicine, and Novel Therapeutic Targets.
|Mr Heath Norman Lee||Chief Financial Officer,Executive Director||Jul 2016||
Mr Heath Norman Lee
Chief Financial Officer,Executive Director
Mr Lee gained his Chartered Accountant qualification working with KPMG before moving into investment banking with BZW (Barclays Bank) which was later acquired by ABN AMRO. As a merger and acquisitions executive, Heath advised the Federal Government of Australia on Phase 1 & 2 privatisation of Australia's airports and CSR on its demerger of Rinker Materials. With experience advising companies in relation to trade sales, mergers & acquisitions and company strategy, Heath left ABN AMRO to launch his own business. Over a period of 9 years, as founder and CEO, Heath built OCIS from a startup contact centre and market research company to a business operating in Australia, New Zealand and Fiji servicing clients such as Optus, The Nielsen Company, Seek.com, Virgin Mobile and the New Zealand Government before the business was sold in 2013.
|Dr Andreas Fouras||Chief Executive Officer,Managing Director||Dec 2012||
Dr Andreas Fouras
Chief Executive Officer,Managing Director
Dr Fouras started his career in academic research studying experimental fluid dynamics in the Department of Mechanical and Aerospace Engineering at Monash University in Melbourne, Australia. His early research in wind tunnel quantification placed him as a young leader in the area of imaging (within fluid dynamics) developing a number of new approaches to the imaging of gas and liquid flow. He held the position of Professor and Director of the Laboratory for Dynamic Imaging. Andreas was recognised by various awards from a range of research bodies including the National Health and Medical Research Council and the American Asthma Foundation. Andreas was able to apply concept to clinical use through the development of XV Technology, measuring airflow within the breathing lungs, at every stage of the breath, with both high spatial and temporal resolution at very low dose. Andreas' research has been documented in over 100 peer reviewed publications and over 40 patents and patent applications. Andreas founded 4DMedical in December 2012. He received Australian Davos Connection Australian Leadership Award (2013).
|Ms Charlene Shia-Ying Stahr||Company Secretary||N/A|
4DX directors must report any change in shareholding to the ASX within 5 business days.
See Director Transactions for all ASX companies.
|07/04/21||Lilian (Lil) Bianchi||Issued||3,306||$1.55||$5,124||Participation in share purchase plan|
|07/04/21||Lusia Guthrie||Issued||2,409||$1.55||$3,733||Participation in share purchase plan|
|07/04/21||Bruce Rathie||Issued||9,638||$1.55||$14,938||Participation in share purchase plan|
The current holdings of 4DX directors.
|Director||Last Notice||Direct Shares||Indirect Shares||Options||Convertibles|
|Lilian (Lil) Bianchi||07/04/2021||N/A||53,306||N/A||N/A|
No Substantial Shareholders for 4DX in our database.
12 month transaction history compiled from ASX announcements.
|Date||Name||Bought||Previous %||New %|
|10-03-21||Perennial Value Management Limited||16,128,334||--||5.35|
|07-08-20||Perennial Value Management Limited||14,526,356||--||5.49|
12 month transaction history compiled from ASX announcements.
|Date||Name||Sold||Previous %||New %|
|07-04-21||Velocimetry Consulting Pty Ltd||7,251,079||50.82||43.2|
|09-12-20||Perennial Value Management Limited||14,526,356||5.49||--|
All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.